Adalimumab in biologic-naïve patients with Crohn's disease after resolution of an intra-abdominal abscess: a prospective study from the GETAID.

Fiche publication

Date publication

janvier 2023

Journal

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Auteurs

Membres identifiés du Cancéropôle Est :
Dr VUITTON Lucine , Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Bouhnik Y, De Chambrun GP, Lambert J, Nachury M, Seksik P, Altwegg R, Vuitton L, Stefanescu C, Nancey S, Aubourg A, Serrero M, Filippi J, Desseaux K, Viennot S, Abitbol V, Boualit M, Bourreille A, Giletta C, Buisson A, Roblin X, Dib N, Malamut G, Amiot A, Fumery M, Louis E, Elgharabawy Y, Peyrin-Biroulet L,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36731588

Résumé

The management of intra-abdominal abscesses complicating Crohn's disease (CD) is challenging and surgery with delayed intestinal resection is often recommended. The aims of this study were to estimate the success rate of adalimumab (ADA) in CD patients with an intra-abdominal abscess resolved without surgery, and to identify predictive factors for success.